Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease

NCT01863147 is registered in ClinicalTrials.gov with Wuhan General Hospital of Guangzhou Military Command as lead sponsor.

NCT NCT01863147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01863147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease
Lead sponsor
Wuhan General Hospital of Guangzhou Military Command
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2013
Completion date
July 31, 2015
Enrollment
66 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease, newly diagnosed type 2 diabetes